Jump to content

GENENTECH TO PRESENT FIRST CLINICAL DATA ON NOVEL ANTI-TIGIT CANCER IMMUNOTHERAPY TIRAGOLUMAB AT ASCO


Recommended Posts

Press Release: 

GENENTECH TO PRESENT FIRST CLINICAL DATA ON NOVEL ANTI-TIGIT CANCER IMMUNOTHERAPY TIRAGOLUMAB AT ASCO

PHASE II CITYSCAPE TRIAL SHOWS PROMISING RESULTS ADDING TIRAGOLUMAB TO TECENTRIQ IN PEOPLE WITH PD-L1-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCERFULL RESULTS WILL BE PRESENTED IN AN ORAL ABSTRACT SESSION AT THE ASCO20 VIRTUAL SCIENTIFIC PROGRAM ORGANIZED BY THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO)

https://www.gene.com/media/press-releases/14852/2020-05-13/genentech-to-present-first-clinical-data

Link to comment
Share on other sites

Archived

This topic is now archived and is closed to further replies.

×
×
  • Create New...

Important Information

By using this site, you agree to our Terms of Use. We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.